181 related articles for article (PubMed ID: 1890139)
1. Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes.
Spruss T; Bernhardt G; Schickaneder E; Schönenberger H
J Cancer Res Clin Oncol; 1991; 117(5):435-43. PubMed ID: 1890139
[TBL] [Abstract][Full Text] [Related]
2. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
Gust R; Faderl M; Schönenberger H
J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
[TBL] [Abstract][Full Text] [Related]
3. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
[TBL] [Abstract][Full Text] [Related]
4. Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.
vom Orde HD; Reile H; Müller R; Gust R; Bernhardt G; Spruss T; Schönenberger H; Burgemeister T; Mannschreck A
J Cancer Res Clin Oncol; 1990; 116(5):434-8. PubMed ID: 2229132
[TBL] [Abstract][Full Text] [Related]
5. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2000 Mar; 333(2-3):69-71. PubMed ID: 10783521
[TBL] [Abstract][Full Text] [Related]
6. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
[TBL] [Abstract][Full Text] [Related]
7. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.
Spruss T; Schertl S; Schneider MR; Gust R; Bauer K; Schönenberger H
J Cancer Res Clin Oncol; 1993; 119(12):707-16. PubMed ID: 8408183
[TBL] [Abstract][Full Text] [Related]
8. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes, III: Evaluation of the mammary tumor inhibiting properties.
Reile H; Spruss T; Müller R; Gust R; Bernhardt G; Schönenberger H; Engel J
Arch Pharm (Weinheim); 1990 May; 323(5):301-6. PubMed ID: 2383173
[TBL] [Abstract][Full Text] [Related]
9. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
von Angerer E; Birnböck H; Knebel N
Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
[TBL] [Abstract][Full Text] [Related]
10. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
Karl J; Gust R; Spruss T; Schneider MR; Schönenberger H; Engel J; Wrobel KH; Lux F; Haeberlin ST
J Med Chem; 1988 Jan; 31(1):72-83. PubMed ID: 3336035
[TBL] [Abstract][Full Text] [Related]
11. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action II: contribution of drug inactivation, cellular drug uptake and sterical factors in the drug-target interaction to the antitumor activity.
Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
Arch Pharm (Weinheim); 2004 Jun; 337(6):349-59. PubMed ID: 15188224
[TBL] [Abstract][Full Text] [Related]
12. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part II: Biological evaluation-in vitro studies on the P 388 D1 leukemia cell line.
Reile H; Müller R; Gust R; Laske R; Krischke W; Bernhardt G; Spruss T; Jennerwein M; Engel J; Seeber S
Arch Pharm (Weinheim); 1990 Mar; 323(3):133-40. PubMed ID: 2344259
[TBL] [Abstract][Full Text] [Related]
13. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part II. Studies on the influence of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) on the specific immune defense in MXT-M-3,2 breast cancer bearing mice.
Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
Arch Pharm (Weinheim); 2000 Dec; 333(12):397-403. PubMed ID: 11199469
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitivity of human MCF-7 breast cancer cells to diastereoisomeric diaqua(1,2-diphenylethylenediamine) platinum(II) sulfates and specific platinum accumulation.
Reile H; Bernhardt G; Koch M; Schönenberger H; Hollstein M; Lux F
Cancer Chemother Pharmacol; 1992; 30(2):113-22. PubMed ID: 1600591
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes.
Kim DK; Kim G; Gam J; Cho YB; Kim HT; Tai JH; Kim KH; Hong WS; Park JG
J Med Chem; 1994 May; 37(10):1471-85. PubMed ID: 8182706
[TBL] [Abstract][Full Text] [Related]
16. Platinum and palladium complexes containing ethylenediamine derivatives as carrier ligands and their antitumor activity.
Lee K; Tashiro T; Noji M
Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):702-3. PubMed ID: 8004720
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of new murine breast cancer cell lines.
Bernhardt G; Beckenlehner K; Spruss T; Schlemmer R; Reile H; Schönenberger H
Arch Pharm (Weinheim); 2002 Mar; 335(2-3):55-68. PubMed ID: 12043456
[TBL] [Abstract][Full Text] [Related]
18. [DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer.
Müller R; Gust R; Bernhardt G; Keller C; Schönenberger H; Seeber S; Osieka R; Eastman A; Jennerwein M
J Cancer Res Clin Oncol; 1990; 116(3):237-44. PubMed ID: 2370248
[TBL] [Abstract][Full Text] [Related]
19. Mammary tumor inhibiting properties of the (S,S)-configurated [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complex.
Spruss T; Gust R; Müller R; Engel J; Schönenberger H
Arch Pharm (Weinheim); 1990 Feb; 323(2):99-102. PubMed ID: 2334275
[TBL] [Abstract][Full Text] [Related]
20. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
Gust R; Karl J; Faderl M; Schönenberger H
Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
